Alliqua’s (ALQA) Buy Rating Reiterated at HC Wainwright
Alliqua Inc. (NASDAQ:ALQA)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report issued on Friday.
A number of other equities analysts also recently issued reports on the company. Zacks Investment Research downgraded Alliqua from a “buy” rating to a “hold” rating in a research report on Friday, August 12th. Chardan Capital reissued a “buy” rating on shares of Alliqua in a research report on Sunday, July 10th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Alliqua currently has an average rating of “Buy” and a consensus target price of $2.50.
Shares of Alliqua (NASDAQ:ALQA) traded down 1.12% during trading on Friday, reaching $0.88. The company’s stock had a trading volume of 98,395 shares. Alliqua has a 12-month low of $0.70 and a 12-month high of $3.82. The stock’s market capitalization is $26.11 million. The firm’s 50-day moving average is $0.91 and its 200-day moving average is $1.00.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/07/alliquas-alqa-buy-rating-reiterated-at-hc-wainwright.html
Alliqua (NASDAQ:ALQA) last released its earnings results on Tuesday, August 9th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.32. Alliqua had a negative return on equity of 53.07% and a negative net margin of 73.41%. The business had revenue of $5.50 million for the quarter, compared to analyst estimates of $5.38 million. Equities analysts expect that Alliqua will post ($0.72) earnings per share for the current year.
A number of large investors have recently modified their holdings of ALQA. Renaissance Technologies LLC increased its stake in shares of Alliqua by 589.0% in the first quarter. Renaissance Technologies LLC now owns 137,800 shares of the company’s stock worth $113,000 after buying an additional 117,800 shares during the last quarter. Suffolk Capital Management LLC increased its stake in shares of Alliqua by 18.0% in the second quarter. Suffolk Capital Management LLC now owns 1,206,127 shares of the company’s stock worth $1,351,000 after buying an additional 184,274 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Alliqua by 1.1% in the second quarter. Vanguard Group Inc. now owns 524,296 shares of the company’s stock worth $587,000 after buying an additional 5,780 shares during the last quarter. Finally, US Bancorp DE increased its stake in shares of Alliqua by 29.8% in the second quarter. US Bancorp DE now owns 181,732 shares of the company’s stock worth $204,000 after buying an additional 41,732 shares during the last quarter. 29.89% of the stock is currently owned by institutional investors.
Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.
Receive News & Ratings for Alliqua Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua Inc. and related companies with MarketBeat.com's FREE daily email newsletter.